Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.38 |
| ▸ | ITGAV | P06756 | 12/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.36 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.33 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904181 | 0.95 | ITGB3 (0.40) | ITGB3ITGAVGPR52ITGA2BITGB6 | |
| SCHEMBL2905461 | 0.90 | ITGB3 (0.34) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2925465 | 0.90 | ITGB3 (0.41) | ITGB3ITGAVGPR52ITGA2BITGB6 | |
| SCHEMBL2906110 | 0.88 | FAAH (0.38) | ITGB3ITGAVGPR52ITGA2BITGB6 | |
| SCHEMBL2907613 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVGPR52ITGA2BITGB6 | |
| SCHEMBL2907973 | 0.84 | ITGB3 (0.38) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2928710 | 0.82 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2925476 | 0.80 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL2906882 | 0.79 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL2927339 | 0.79 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217569-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009058314-A1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| EP-2217569-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885GPR52 230/4885 |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | ITGA5, ITGA1, ITGB5 | ITGB3 13/4885ITGAV 8/4885GPR52 205/4885 |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885GPR52 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.